GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ChromaDex Corp (NAS:CDXC) » Definitions » Net-Net Working Capital

ChromaDex (ChromaDex) Net-Net Working Capital : $0.18 (As of Mar. 2024)


View and export this data going back to 2008. Start your Free Trial

What is ChromaDex Net-Net Working Capital?

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.

ChromaDex's Net-Net Working Capital for the quarter that ended in Mar. 2024 was $0.18.

The industry rank for ChromaDex's Net-Net Working Capital or its related term are showing as below:

CDXC's Price-to-Net-Net-Working-Capital is ranked worse than
87.46% of 933 companies
in the Biotechnology industry
Industry Median: 4.2 vs CDXC: 20.17

ChromaDex Net-Net Working Capital Historical Data

The historical data trend for ChromaDex's Net-Net Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ChromaDex Net-Net Working Capital Chart

ChromaDex Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net-Net Working Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.10 0.04 0.19 0.12 0.16

ChromaDex Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net-Net Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.14 0.14 0.15 0.16 0.18

Competitive Comparison of ChromaDex's Net-Net Working Capital

For the Biotechnology subindustry, ChromaDex's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ChromaDex's Price-to-Net-Net-Working-Capital Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ChromaDex's Price-to-Net-Net-Working-Capital distribution charts can be found below:

* The bar in red indicates where ChromaDex's Price-to-Net-Net-Working-Capital falls into.



ChromaDex Net-Net Working Capital Calculation

ChromaDex's Net-Net Working Capital (NNWC) per share for the fiscal year that ended in Dec. 2023 is calculated as

Net-Net Working Capital(A: Dec. 2023 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(27.173+0.75 * 5.234+0.5 * 14.525-26.508
-0-0)/74.981
=0.16

ChromaDex's Net-Net Working Capital (NNWC) per share for the quarter that ended in Mar. 2024 is calculated as

Net-Net Working Capital(Q: Mar. 2024 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(27.413+0.75 * 6.604+0.5 * 12.495-25.128
-0-0)/75.153
=0.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.

In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

This is a conservative way of estimating the company's value.


ChromaDex  (NAS:CDXC) Net-Net Working Capital Explanation

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.


ChromaDex Net-Net Working Capital Related Terms

Thank you for viewing the detailed overview of ChromaDex's Net-Net Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


ChromaDex (ChromaDex) Business Description

Traded in Other Exchanges
Address
10900 Wilshire Boulevard, Suite 600, Los Angeles, CA, USA, 90024
ChromaDex Corp is a bioscience company dedicated to healthy aging. It is engaged in research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. The company is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen. The company has three reportable segment namely Consumer Products, Ingredients segment and Analytical Reference Standards and Services. Majority of the revenue is earned from Consumer Products segment.
Executives
Brianna Gerber officer: SVP Finance / Interim CFO C/O CHROMADEX, INC., 1735 FLIGHT WAY, SUITE 200, TUSTIN CA 92782
Champion River Ventures Ltd 10 percent owner C/O 7F, CHEUNG KONG CENTER, 2 QUEEN'S ROAD, CENTRAL K3 00000
Jaksch Frank L Jr director, 10 percent owner, officer: Chief Executive Officer 10005 MUIRLANDS BOULEVARD, SUITE G FIRST FLOOR, IRVINE CA 92618
Robert N Fried director 100 NORTH CRESCENT DRIVE, BEVERLY HILLS CA 90210
Steven D Rubin director OPKO HEALTH, INC., 4400 BISCAYNE BLVD., MIAMI FL 33137
Li Ka Shing 10 percent owner 79 DEEP WATER BAY ROAD, HONG KONG F4 00000
Chau Hoi Shuen Solina Holly 10 percent owner SUITES PT. 2909 & 2910, HARBOUR CENTRE, 25 HARBOUR ROAD, WANCHAI K3 999077
Hamed Shahbazi director C/O CHROMADEX, INC., 1735 FLIGHT WAY, SUITE 200, TUSTIN CA 92782
Ann Cohen director C/O CHROMADEX CORPORATION, 10900 WILSHIRE BLVD. STE 600, LOS ANGELES CA 90024
Kristin Patrick director 3329 CAY DRIVE, SHERMAN OAKS CA 91423
Ng Wang Yu Gary director ROOM 1709 HARBOUR CENTER, 25 HARBOUR ROAD, WANCHAI K3 -
Caroline S Levy director 2424 N FEDERAL HIGHWAY, SUITE 208, BOCA RATON FL 33431
Stephen A Block director INTERNATIONAL FLAVORS & FRAGRANCES INC., 521 WEST 57TH ST, NEW YORK NY 10019
Lisa Hatton Harrington officer: General Counsel 53 SEA TERRACE, NEWPORT COAST CA 92657
Kevin M Farr officer: Chief Financial Officer MATTEL, INC., 333 CONTINENTAL BLVD, M1-1518, EL SEGUNDO CA 90245

ChromaDex (ChromaDex) Headlines

From GuruFocus